ArticleJAMA oncology2023
Atezolizumab Plus Bevacizumab in TMB-High Non-Small Cell Lung Cancers-The Hunt for Predictive Biomarkers to Optimize Treatment Selection.
Biagio Ricciuti et al.PubMed ↗Publisher ↗
No numbers read from the abstract.
2 papers cite it
this papercites it